Project Grant R41CA310331
Award Date 9/10/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Norristown, PA, USA
Similar Awards
- This $1,313,567 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Cytoagents Inc., a Pittsburgh-based pharmaceutical company, in developing CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy. CRS is a severe and potentially life-threatening immune-mediated toxicity that can occur with CAR T-cell treatments for hematologic malignancies. The...
- The National Cancer Institute (NCI) awarded a $402,600 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The primary goals of this 5-year project are to develop these CAR T-cell therapies and investigate the mechanism by which U5 snRNP is...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Aerocytek, Inc. to develop an innovative approach for point-of-care autologous CAR-T cell manufacturing. The project aims to overcome current challenges in large-scale production and integration of CAR-T cell therapies by leveraging targeted microbubble-based technologies for T cell selection, activation, and transduction. This solution seeks to democratize the...
- The University of Maryland, Baltimore received a $422,799 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on therapeutic targeting and biophysical characterization of chimeric antigen receptor (CAR)-mediated trogocytosis. The project aims to investigate the molecular basis of CAR-mediated trogocytosis, a mechanism of resistance to CAR T cell therapy, and explore alternative approaches to selectively inhibit this process and enhance...
- The U.S. National Cancer Institute (NCI) has awarded a $398,997 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Immunogenik, Inc. to enhance cancer therapeutics with a novel 3-in-1 chimeric antigen receptor (CAR) T cell approach. The research aims to target tumor-associated myeloid cells, which can suppress anti-tumor immune responses, by inhibiting the immunosuppressive LAIR1 signaling pathway. Key deliverables include demonstrating the efficacy of LAIR1...
- The federal Project Grant award titled "HARNESSING B CELLS AFTER STEM CELL TRANSPLANT TO PRODUCE NOVEL CAR-TS" is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for a total of $415,257. The project period runs from July 3, 2025 to June 30, 2027. The award aims to leverage insights into B cell tolerance mechanisms after hematopoietic stem cell transplantation to engineer less toxic, more targeted immune cells that can eradicate hematological...
- This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
- The National Cancer Institute awarded a $176,040 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) from July 1, 2025 to June 30, 2027 under the Cancer Research Manpower (CFDA 93.398) federal grant program. The goal of this project is to develop new strategies to engineer CAR-T cells that can overcome the cancer cell glycocalyx barrier in solid tumors. This will involve: (1) engineering CAR-T cells to strengthen the immune synapse by enhancing binding to the...
- The National Cancer Institute (NCI) awarded Lifengine Animal Health Laboratories Incorporated a $400,000 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395). The award period runs from August 4, 2025 to July 31, 2026. The grant funds the development of chimeric antigen receptor (CAR)-T cell therapies that can overcome functional exhaustion by overexpressing the C-MYB transcription factor. This research aims to improve the therapeutic efficacy and duration of...
- This $438,900 Project Grant was awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The grant funds research to develop a "three-cell (T-NK-macrophage) immunotherapy system" using chimeric antigen receptor (CAR) and synthetic cytokine receptor (SCR) technologies. The primary goal is to engineer the three immune cell types to function...